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Tolerance to morphine analgesia is believed to result from a neuronal adaptation produced by continuous drug administration, although the precise mechanisms
involved have yet to be established.
Recently, we reported selective alterations in rat spinal calcitonin gene-related peptide (CGRP) markers in morphine-tolerant animals. In fact, increases in CGRP-like immunostaining and decrements in specific ['251 ]hCGRP binding in the superficial laminae of the dorsal horn were correlated with the development of tolerance to the spinal antinociceptive action of morphine. Other spinally located peptides such as substance P, galanin, and neuropeptide Y were unaffected. Thus, the major goal of the present study was to investigate whether the development of tolerance to spinally infused morphine could be modulated by the blockade of dorsal horn CGRP receptors using the potent CGRP antagonist hCGRP,-,,.
Indeed, cotreatments with hCGRP,,, prevented, in a dosedependent manner, the development of tolerance to morphineinduced analgesia in both the rat tail-flick/tail-immersion and paw-pressure tests. Moreover, alterations in spinal CGRP markers seen in morphine-tolerant animals were not observed after a coadministration of morphine and hCGRP,-,,. These results demonstrate the existence of specific interaction between CGRP and the development of tolerance to the spinal antinociceptive effects of morphine. They also suggest that CGRP receptor antagonists could become useful adjuncts in the treatment of pain and tolerance to the antinociceptive effects of morphine.
Key words: analgesia; autoradiography; immunostaining; spinal cord; opioids; tolerance Morphine is used widely in the clinical management of various types of pain, including as an adjunct in the treatment of cancer (Trachtenberg, 1994) . Although morphine is very useful as an analgesic, its clinical application in chronic pain is limited by rapid development of tolerance to its antinociceptive properties (Johnstone and Smith, 1992) . The basis of tolerance to the antinociceptive actions of morphine and related opioids is only poorly understood (Collier and Schneider, 1969; Yaksh and Noueihed, 1985; Rasmussen et al., 1990; Yamamoto and Meltzer, 1992) . For example, although a possible role for brain and spinal cord opioid receptors in tolerance has been proposed (Holt et al., 1975; Pert and Snyder, 1976; Werling et al., 1989) , clear evidence for their direct involvement and that of opioid receptor-linked transduction mechanisms (De Vries et al., 1991) is still mostly lacking. Recently it was proposed that tolerance to the antinociception of morphine could be mediated, at least in part, through the activation of physiologically antagonistic systems and/or the inhibition of facilitatory ones (Lake et al., 1991; Trujillo and Akil, 1991; Gutstein and Trujillo, 1993; Rezayat ct al., 1994; Stanfa et al., 1994) ; however, potential antagonistic factors that may be active against tolerance, such as neuropeptide FF (Lake et al., 1991) or Recei ved July 10, 1995; revised Jan. 1 I, 1996; acccptcd Jan. 17, 1996 (Rezayat et al., 1994) , potentiated morphine analgesia in naive animals (Gouardkres et al., 1993b; Rezayat et al., 1994; Stanfa et al., 1994) . Thus, recent interest has focused on the possible role of substance P (SP) in the antinociception and tolerance to the spinal effects of morphine, because this neuropeptide is one of the major sensory peptides modulating pain transmission (Hem-y, 1976) . Consistent alterations in spinal SP markers, however, have not been observed in morphine-tolerant animals (Gouardkres et al., 1993a; MCnard et al., 1995a) .
Calcitonin gene-related peptide (CGRP) is known to be colocalized with SP and glutamate and co-released with SP from primary afferent fibers in the dorsal horn of the spinal cord (Gibson et al., 1984; Woolf and Wiesenfeld-Hallin, 1986) . Specific CGRP receptor binding sites are concentrated in the dorsal horn of the spinal cord (Yashpal et al., 1992) . Additionally, CGRP induces algesic effects in certain models of nociception (Cridland and Henry, 1988) and modulates acute antinociceptive action of opioid agonists (Welch et al., 1989) . In fact, CGRP inhibits the antinociception produced by morphine (Welch et al., 1989) , whereas this opiate inhibits the acute release of CGRP in the cord (Pohl et al., 1989) . Recently, we reported that increases in CGRPlike immunostaining and reductions in specific ["'I]hCGRP binding in the superficial laminae of the dorsal horn were correlated with the development of tolerance to the spinal antinociceptive action of morphine (M6nard et al., 1995a) Behavioral evaluation ofnociception. For nociceptive studies, animals in the various groups were monitored on a daily basis, using cithcr the tail-immersion/tail-flick (analgesimetric test) or paw-pressure tests.
Tail-immersion test. In the tail-immersion test, the animal held by the experimenter was lowered so that its tail was immersed in a bath of water maintained at a constant temperature of 49°C. The time needed to elicit a nociceptive response (tail flick or whole-body jerk) was noted (cutoff time, 30 set). At the end of the chronic infusion period, some groups of rats were pcrfuscd intracardially or killed by decapitation, and their spinal cords were proccsscd for either CGRP-like immunohistostaining or in vitro receptor autoradiography (see below).
Tail-jfick test. The tail-flick test (D'Amour and Smith, 1941) was used to evaluate the nociceptive response to a focused thermal stimulus. Radiant heat was applied to the base of tail using an analgesia meter (Owen et al., 1981) with the heat source intensity adjusted to provide a baseline response latency of 2-3 set and the cutoff time set at 10 sec.
Paw-pressure test. The paw-pressure test used to evaluate the response to a mechanical nociceptive stimulus was a modification of the classic test described by Randall and Selitto (1957) . The animal was held gently, and mechanical pressure was applied to the dorsal surface of a noninflamed hindpaw using an air-filled syringe held in an inverted position and DAYS connected to a pressure gauge. The pressure in the syringe was gradually increased until a paw-withdrawal response was observed. The pressure was released immediately after this, and the value on the gauge producing response was recorded.
In cxpcrimcnts with morphine and CGRP-related peptides, the maximum pressure that elicited withdrawal response was 300 mmHg (cutoff pressure value). In untreated animals, highly reproducible threshold values of pressure were observed when animals were tcstcd on a daily basis.
In the latter two nociceptivc tests, baseline response latencies were determined before implantation of minipumps. In implanted animals, antinociception was evaluated once daily bctwccn 9 and 10 A.M. and paw-pressure tests. The treatment groups were saline (0.9%, 1 mlihr, n = 8), morphine (7.5 &hr, n = 6) morphine (same dose) + CGRPs-,, (0.5 kgfhr, n = 7), and morphine (same dose) + CGRPsel, (1.0 pg/hr, n = 7). All animals were tested once daily in both antinociception tests as described above. On day 5 of infusion, the intrathecal infusion catheter was severed from the minipump to allow acute injections. The residual solution present in the infusion catheter was removed by flushing the catheter three times at 2 hr intervals with 5 ml of saline. This procedure avoided the occurrence in morphine-infused rats of intense alladynia when all of the residual morphine was flushed into the intrathecal space. Twenty-four hours after detachment of the catheter, cumulative dose-response curves for acute intrathecal morphine were delivered as described by Mao et al. (1995 To assess the potential effects of intrathecal infusions on motor function, the animals were tested in an inclined plane test (Rivhn and Tater, 1977) which has been used to evaluate this behavior in rats with spinal cord injury. Each animal used in the tail-flick and paw-pressure tests was placed on an inclined plane, the angle of which was gradually increased from a horizontal to a vertical position. The maximal angle at which the animal maintained its position on the plane was determined.
Each animal was assessed daily in this test. The test was conducted in a single-blind fashion such that the assessor was unaware of the trcatmcnt received by the animal. CGIWlike immunostaining.
At the end of the 7 d infusion, rats from the saline-treated control group (n = 6) and the various experimental groups (n = 4-6 per group) used in the tail-immersion test were anesthetized with sodium pentobarbital (65 mgikg) and perfused intracardially with Bouin's solution, and the lumbar (LA) segment of the spinal cords was dissected out and postfixed in the same fixative for 2 hr. Samples were then cryoprotected, cut serially (20 pm) in the transverse plane, and processed for immunohistochemistry as described in detail elsewhere (Kar et al., 1989) . In brief, sections were incubated with polyclonal antisera to rat CGRP (1:2000) (Gibson et al., 1984) at 4°C for 48 hr, washed in PBS, pH 7.4, and incubated for 45 min with goat anti-rabbit IgG (1:25). After washing in PBS, slides were incubated in PAP complex (1:50) for 45 min and then developed in DAB according to the glucose oxidase-nickel enhancement method. The characteristics and specificity of the antiserum used have been described in detail elsewhere and Polak, 1986) . Sections were then dehydrated in graded alcohols, cleared in xylene, and mounted in Pcrmount before microscopic examination.
In vitro CGRP receptor uutorudiogruphy. At the end of the 7 d infusion, rats from the saline-treated control group (n = 6) and the various experimental groups (n = 4-6 per group) used in the tail-immersion test were decapitated, and L4 segments of the spinal cords were snap-frozen in 2-methyl butane at ~40°C. Tissues were then serially cut (20 pm), thaw-mounted on gelatin-coated slides, and proccsscd for receptor autoradiography using 50 PM ['Z51]hCGRP as described in detail clscwhcrc (MCnard et al., 1995a Tail-immersion test Figure 1 shows the effects of morphine infusions with and without hCGRP,-,, in the tail-immersion test. Morphine (7.5 pg/hr) produced a peak increase in latency to response on day 3. The response returned to baseline value despite continued morphine infusion, reflecting the development of tolerance to the antinociceptive action of morphine. Co-infusion of hCGRP,-,, (0.25 to 2.0 pg/hr) with morphine did not alter the peak antinociceptive response but significantly (1.0 and 2.0 &hr) delayed its decline, reflecting the inhibition of tolerance to the effect of morphine. In contrast, a co-infusion of CGRP with morphine abolished the morphine response (not shown). Saline (Fig. l) , CGRP,_,, (not shown), and hCGRP, when infused alone (not shown), did not influence nociceptive response in this test. After completion of the behavioral test, these groups of animals were perfused or killed to 
Tail-flick and paw-pressure tests
The potential of hCGRP,-,, to influence morphine antinociccptive action was evaluated further in the continuous infusion model using the tail-flick and paw-pressure tests. The animals were infused with two doses of morphine (7.5 and 10.0 ~gimlihr) to produce antinociceptive responses of different magnitude. In animals receiving infusion of the lower dose of morphine (Fig. 2 ) the antinociceptive response in both tests was submaximal; it peaked at day 3 and declined thereafter to baseline value by day 6. Co-infusion of this dose of morphine with CGRP,-a, (0.5 and 1.0 pg/ml/hr) did not alter significantly the peak response to morphine infusion; however, it delayed significantly the decline of response seen in animals receiving morphine alone ( Fig. 2A,B) . Thus, CGRP,-a, markedly attenuated the development of tolerance to a submaximal dose of morphine in the tail-flick and paw-pressure tests.
In animals receiving infusion of the higher dose of morphine, the peak antinociceptive in both tests reached a near-maximal value. As in the preceding tests, this response declined after day 3 and returned to baseline value by day 6 (Fig. 3A,B) . Co-infusion of hCGRP,m,, with this dose of morphine did not influence the magnitude of the antinociceptive response in the two tests; however, the decline of the morphine-induced antinociception from peak to baseline level occurring during the 3 d period was slowed significantly by the co-infusion. Thus, CGRP,_,, inhibited the development of tolerance to a dose of morphine, producing a near-maximal response.
Dose-response experiments The cumulative dose-response curves for acute action of morphine after chronic intrathecal infusion of saline, morphine alone, and in combination with two CGRP,-a, doses are illustrated in Figure 4 . The ED,, values for acute intrathecal morphine are represented in Table 1 . As shown, intrathecal injection of morphine produced dose-related antinociception in the tail-flick and paw-pressure tests. The dose-response curve for morphine action in animals infused with the opiate for 5 d showed a four-and threefold shift to the right in the tail-flick and paw-pressure tests, respectively. The increase in ED,,, value in the morphine group is indicative of tolerance to the action of acute morphine. In animals co-infused with morphine and CGRP,-,,, using the 0.5 and 1.0 pg/hr dose, the dose-response curve for morphine showed a smaller shift or an overlap with the curve obtained in the saline group. The EDS,, values for morphine action in this group (Table  1) were significantly lower than those obtained in the morphineinfused group, reflecting attenuation or blockade of the development of tolerance by CGRP,-,,.
Action of CGRP,,, and morphine on motor function The motor function of animals undergoing morphine infusions with and without CGRP,_,, was evaluated in the inclined-plane test to determine whether the tolerant or nontolerant animals exhibited deficits in this function (data not shown). The animals infused with morphine tolerated a slope angle of -70" in the inclined plane before falling off the plane. During infusion, this value did not vary significantly, regardless of the morphine dose. Animals co-infused with CGRP,-a, (0.5 or 1.0 pg/hr) also tolerated a similar angle of slope. The values obtained on successive days after the beginning of the co-infusion were not significantly different from those obtained in the preceding tests. Thus, the motor performance of animals receiving morphine with and without CGRP,-a, was not significantly different. Visual examination of fore and hind limbs of animals did not reveal signs of dysfunction. At the completion of these experiments, dye-injection experiments revealed the presence of intrathecal catheter at the lumbar level.
Spinal CGRP-like immunostaining in treated animals As is already well established (Gibson et al., 1984) , CGRP-like immunostaining was found to be concentrated in the superficial laminae of the dorsal horn of the spinal cord (Fig. 5A) . A marked increase in CGRP-like immunostaining was seen in superficial laminae of the dorsal horn after a 7 d intrathecal infusion with morphine ( Fig. 5B ). This increase was inhibited by a co-infusion with the CGRP antagonist hCGRP,-,, (Fig.  5C ) but not with CGRP itself (Fig. 5D) . A slight decrease in CGRP-like immunostaining was also observed in laminae I and II of the spinal cord after a 7 d infusion with hCGRP alone (Fig. 5F) ; however, this was not seen after infusion with the antagonist hCGRP,-,, (Fig. 5E ).
Spinal CGRP receptors in treated animals In accordance with previous results (Sexton et al., 1986; Kruger et al., 1988; Yashpal et al., 1992) specific ['2sI ]hCGRP binding sites in the spinal cord of saline-treated rats are concentrated in the dorsal horn (Fig. 6A) . The decrease in [""I]hCGRP binding obscrvcd in superficial laminae of morphine-treated animals (Figs. 6B, 7) was apparently reversed by a co-infusion with hCGRP,_,, (Figs. 6C, 7) and was enhanced by a co-infusion with hCGRP (Figs. 60, 7) . When infused alone, hCGRP,-3, failed to have any significant effect on ["'I]hCGRP binding (Figs. 6E, 7) , but under similar conditions hCGRP decreased labeling in all layers, as expected for a full agonist (Figs. 6F, 7) .
With the focus on substantia gelatinosa and lamina X, the amounts of specific binding for [ '2"I]hCGRP among the salinetreated and the two morphine plus peptide-treated groups were compared. A 7 d treatment with morphine induced a significant decrease in [i2"I]hCGRP binding in laminae I, II, and III without affecting labeling in lamina X (Fig. 7) . A co-infusion with hCGRP,-,, reversed the effects of morphine (Fig. 7 ) whereas a cotreatment with the agonist hCGRP had a somewhat additive (7.5 &hr) (B), morphine (7.5 pg/hr) plus hCGRP,-,, (1.0 Fg/hr) (C), morphine (7.5 pg/hr) plus hCGRP (1.0 &hr) (D), hCGRP,-,, (1.0 &hr) (E), and hCGRP (1 .O &hr) (8') after a 7 d continuous infusion.
At least four to six animals per group were studied, all showing the changes depicted in these representative photomicrographs.
[i2'I]hCGRP binding in laminae I, II, and III, as well as in lamina X, whereas a treatment with hCGRP,-,, by itself was devoid of effects on [""I]hCGRP binding (Fig. 7) .
DISCUSSION
The present study demonstrates that an intrathecal co-infusion of morphine and CGRP,,,, a CGRP receptor antagonist, for 7 d blocks or significantly delays the development of tolerance to the antinociceptive effect of morphine. The inhibition of tolerance to morphine was also reflected in responses obtained with acute intrathecal morphine postinfusion. CGRP,-,, reduced or prevented the increase in ED,, dose of acute intrathecal morphine produced by the chronic infusion of the opiate for 5 d. These findings were apparent in at least the two types of nociceptive tests involving thermal and mechanical nociceptive stimuli. Thus, the capacity of the CGRP receptor antagonist to attenuate the development of tolerance to morphine analgesia was not dependent on the nature of the applied nociceptive stimuli (heat or pressure).
CGRPs-w did not increase the antinociception produced by morphine and did not induce motor deficit, alone or in combination, in the inclined-plane test. The attenuation of tolerance thus was not related to other factors such as an enhancement of morphine response or motor deficits. These observations suggest that CGRP,,, has a highly selective action through which it can inhibit tolerance without enhancing the magnitude of the antinociceptive effects. Interestingly, Yu et al. (1994) demonstrated recently that hCGRP,,, increases paw-withdrawal latency, and a high dose of this peptide (15 pg) attenuated SP-induced hyperalgesia. At the low doses used here, however, hCGRP,_,, failed to influence nociception in three different tests over a 6-7 d period. Thus, under our conditions, CGRP,-a, is most unlikely to modulate morphine tolerance by itself, influencing nociception in keeping with the usual, rather limited effects of most antagonists (e.g., naloxone, neurokinin blockers) under basal, nonstimulated/ unchallenged conditions. The selective alterations in spinal CGRP-like immunostaining and [r2'I]hCGRP binding, recently reported to occur after the intrathecal infusion of morphine (Menard et al., 1995a) , were also observed in the present study and were reversed by a cotreatment with CGRP,-a,. Taken together, these observations support the existence of a unique interaction between the spinal CGRP sys- (Menard et al., 1995b) . Indeed, we have reported recently that various other peptides known to be present in sensory primary afferent fibers were not altered significantly during the development of tolerance to the spinal antinociceptive properties of morphine. In contrast, spinal CGRP-like immunostaining was enhanced and ['251]h-CGRP binding was reduced, changes which paralleled the loss of morphine effect in the tail-immersion test (Menard et al., 1995a) . The reversal of these changes by CGRP,-,, suggests that alterations in CGRP-like immunostaining and receptor binding contribute to the development of tolerance to morphine analgesia.
Because CGRP is a well known vasodilator substance (Poyner, 1992) it is difficult to exclude fully the participation of the vasculature in the observed effects of CGRPs-a, on the development of tolerance to the spinal antinociceptive properties of morphine. The fact that the CGRP antagonist was as effective in two very different pain-related paradigms (tail immersion and paw pressure), however, suggests that a significant involvement of the vasculature is unlikely. Additionally, unlike CGRP, the markers for several other well established vasoactive peptides such as SP, neurotensin, and neuropeptide Y in the dorsal horn were not altered during the development of tolerance to spinal morphine antinociception, suggesting that involvement of cardiovascular parameters is unlikely to be a major factor in CGRP,-,,-related blockade of tolerance to morphine.
Modifications in CGRP like-immunostaining and binding in morphine-tolerant animals were restricted to laminae I, II, and III. These regions, among others, are known to be involved in the processing of nociceptive information (Yaksh and Noueihed, 1985) . Because morphine-sensitive opioid receptors are located at least partly on primary afferent nerve terminals (Yaksh and Noueihed, 1985; Gouarderes et al., 1993a; Arvidsson et al., 1995) and their activation acutely inhibits the release of CGRP (Pohl et al., 1989) , the apparent increase in CGRP-like immunostaining in morphine-tolerant animals may be related to the continuous inhibition of its release. This seems rather unlikely, however, as increased receptor densities would be expected under conditions of low transmitter release. In fact, the opposite was observed after morphine treatment, with the densities of [iz51]hCGRP binding being reduced in superficial laminae of the tolerant animals. A more likely explanation is that although morphine acutely inhibits CGRP release from primary afferent terminals, this mechanism becomes inoperant in tolerant rats. Thus, the loss of this inhibitory influence of morphine would lead to augmented CGRP synthesis or release leading to a receptor downregulation to avoid overstimulation. Indeed, the observed increase in CGRP-like immunostaining supports this explanation. In the presence of a CGRP receptor antagonist (hCGRP,m,7), the overactivation and subsequent downregulation of the CGRP receptors presumably would not occur, and a tightly controlled synthesis and release of CGRP from primary sensory afferent fibers would be maintained. CGRP,-,, could be reversing alterations induced by chronic morphine in spinal CGRP markers by acting on receptors located either pre-or postsynaptically, the presynaptic ones acting as autoreceptors involved in the regulation of the synthesis and release of CGRP. Experiments are currently in progress to investigate this possibility.
Recently, the administration of NMDA receptor antagonists was reported to block tolerance to morphine analgesia at the spinal level, suggesting a role for glutamate or related transmitters in this phenomenon (Trujillo and Akil, 1991; Gutstein and Trujillo, 1993; Mao et al., 1994) . Because CGRP is colocalized with glutamate in primary afferents (DeBiasi and Rustoni, 1988; Merghi et al., 1991) augments the response of dorsal horn neurons to NMDA (Murase et al., 1989) and releases glutamate (Kangrga et al., 1990) , the changes in CGRP seen in this study may be mediated by glutamate. The role of glutamate in this regard is unclear, however, because we failed to obtain any evidence for an effect of spinally infused glutamate agonists or antagonists on spinal CGRP markers (our unpublished results) and because NMDA receptor blockers increase morphine catalepsy and lethality (Trujillo and Akil, 1990) .
Postreceptor mechanisms involved in the antimorphine tolerance properties of CGRP,_,, remain to be established. One possible mechanism by which CGRP could modulate the action of morphine (and of its tolerance) is the activation of the nitric oxide synthase (NOS) pathway in primary afferent terminals. Recent evidence shows that NO can be produced by cultured dorsal root ganglia, and NOS-immunoreactive neurons are present in both neonatal and adult dorsal root ganglia, suggesting that NO likely act as an important signaling molecule in the dorsal horn of the spinal cord (Meller and Gebhart, 1993) . In fact, a recent study demonstrated an increase in spinal CGRP release after the administration of sodium nitroprusside, a NO producer (Garry et al., MBnard et al. l 1994). It has also been proposed that CGRP receptors may be coupled to cGMP production (Poyner, 1992) a second messenger whose levels are elevated by NOS activity (Garthwaite, 1991) . It is thus possible that morphine could modulate spinal cord CGRP markers by influencing NO. It could be speculated that tolerance to morphine would increase NO synthesis and alter the release of CGRP from primary afferents. Interestingly, recent data showed that blockers of NO synthesis can retard the development of tolerance to the antinociceptive effects of systemic morphine (Kolesnikov et al., 1992) . These findings are rather similar to the effects reported here for hCGRP,_,, on spinally infused morphine. Moreover, Kolesnikov et al. (1993) demonstrated that established morphine tolerance could be reversed by inhibition of NO production. Because this reversal phenomenon was very slow in onset, it likely involved several steps subsequent to the modulation of NOS, because the inhibition of this enzyme should have rapidly reinstated the analgesic properties of opioids if NO was the sole mediator involved in tolerance to opioids. Hence CGRP could play a role in that regard, and hCGRP,-,,, by blocking its receptors, could interfere with the synthesis of NO and restore the antinociceptive properties of morphine. In summary, the present data reveal the existence of a novel interaction between CGRP and the development of tolerance to the antinociceptive effects of morphine in the rat spinal cord. The findings in two different pain-related tests that a CGRP receptor antagonist can retard or block the development of tolerance to morphine is likely of significance for a better management of pain in some clinical conditions. In that regard, the design of nonpeptide CGRP,-a, homologs is being pursued actively in our laboratories. 
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